Related references
Note: Only part of the references are listed.Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer
Tien-Hua Chen et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)
Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types
X. Zhao et al.
ANNALS OF ONCOLOGY (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sunitinib in the Treatment of Thyroid Cancer
Silvia Martina Ferrari et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors
Rodrigo Barbosa de Aguiar et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer
Peter H. Ahn et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Edwin P. Hui et al.
CLINICAL CANCER RESEARCH (2018)
Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
Douglas Adkins et al.
LANCET ONCOLOGY (2018)
Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma
Min Kang et al.
MEDICINE (2018)
Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
Yuhei Kogata et al.
Oncotarget (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Giorgia Marisi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Drug review: Pazopanib
Shingo Miyamoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
Qiuyan Chen et al.
CANCER COMMUNICATIONS (2018)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
Ziad Hussein et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
Sorafenib: A Review in Hepatocellular Carcinoma
Gillian M. Keating
TARGETED ONCOLOGY (2017)
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review
Dinesh Kumar Chellappan et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma
Vasiliki A. Papadimitrakopoulou et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Phase II trial of bevacizumab plus cetuximab plus cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma
Matthew G. Fury et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
Yassine Lalami et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck canceraEuro
A. Argiris et al.
ANNALS OF ONCOLOGY (2016)
Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
Zhexuan Lin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2016)
Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
Sai Ge et al.
ONCOLOGY LETTERS (2016)
Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
Amit Walia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2015)
Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study
Gemma Gatta et al.
EUROPEAN JOURNAL OF CANCER (2015)
Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion
Matthew J. Nyflot et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
Paul L. Swiecicki et al.
INVESTIGATIONAL NEW DRUGS (2015)
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Assuntina G. Sacco et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting angiogenesis in head and neck cancer
Maria Vassilakopoulou et al.
ORAL ONCOLOGY (2015)
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
Jill Gilbert et al.
ORAL ONCOLOGY (2015)
Selective use of vandetanib in the treatment of thyroid cancer
Poupak Fallahi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck
Min Yao et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Multicenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma
Wen Ye et al.
MOLECULAR THERAPY (2014)
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma
C. Xue et al.
ANNALS OF ONCOLOGY (2013)
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A. Argiris et al.
ANNALS OF ONCOLOGY (2013)
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Tanguy Seiwert et al.
INVESTIGATIONAL NEW DRUGS (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Phase II Trial of Endostar Combined With Gemcitabine and Cisplatin Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NCT01612286)
Ting Jin et al.
ONCOLOGY RESEARCH (2013)
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
Sewanti Limaye et al.
ORAL ONCOLOGY (2013)
A Phase 2 Study of Bevacizumab With Cisplatin Plus Intensity-Modulated Radiation Therapy for Stage III/IVB Head and Neck Squamous Cell Cancer
Matthew G. Fury et al.
CANCER (2012)
E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma
Z. Adhim et al.
CANCER GENE THERAPY (2012)
Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
David S. Yoo et al.
CLINICAL CANCER RESEARCH (2012)
Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-β1 (TGF-β1)
M. Victoria Recouvreux et al.
ENDOCRINOLOGY (2012)
Enhancement of radiation response with bevacizumab
Tien Hoang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
Nancy Y. Lee et al.
LANCET ONCOLOGY (2012)
Angiogenesis in Head and Neck Cancer: A Review of the Literature
Codeca Carla et al.
JOURNAL OF ONCOLOGY (2012)
Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation
E. P. Hui et al.
ANNALS OF ONCOLOGY (2011)
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers
J. K. Salama et al.
ANNALS OF ONCOLOGY (2011)
Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck A Phase II Trial of the Sarah Cannon Oncology Research Consortium
John D. Hainsworth et al.
CANCER JOURNAL (2011)
A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
Wan-Teck Lim et al.
CLINICAL CANCER RESEARCH (2011)
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
George Fountzilas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase II study of sunitinib malate in head and neck squamous cell carcinoma
Nicholas W. Choong et al.
INVESTIGATIONAL NEW DRUGS (2010)
Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420
Stephen K. Williamson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Jean-Pascal H. Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Ezra E. W. Cohen et al.
LANCET ONCOLOGY (2009)
Axitinib for renal cell carcinoma
Guru Sonpavde et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Targeting angiogenesis in head and neck cancer
Tanguy Y. Seiwert et al.
SEMINARS IN ONCOLOGY (2008)
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
Christine Elser et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses
E. Winquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
Matthew G. Fury et al.
INVESTIGATIONAL NEW DRUGS (2007)
Recent advances in the therapy of renal cancer
Guru Sonpavde et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
J. A. Gietema et al.
ANNALS OF ONCOLOGY (2006)
Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action
J Folkman
EXPERIMENTAL CELL RESEARCH (2006)
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck
MM Cooney et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Endostatin's antiangiogenic signaling network
A Abdollahi et al.
MOLECULAR CELL (2004)
Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2,-9, and-13
P Nyberg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma
BD Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
